PATENT CLAIM ANALYSIS

Application Number: 16060250
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["544", "278000"]

Abstract:
The present invention relates to a novel dihydropyranopyrimidinone derivative, a tautomer thereof, a stereoisomer thereof and their mixture, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a tankyrase-related disease, which contains the same as an active ingredient.

Claim (Index 7):
The pharmaceutical composition according to  claim 6 , wherein the cancer is selected from a group consisting of a cancer of head, neck, eyes, mouth, throat, esophagus, bronchus, larynx, pharynx, chest, bone, lungs, colon, rectum, stomach, prostate, bladder, uterine, cervix, breast, ovaries, testices or other reproductive organs, skin, thyroid, blood, lymph nodes, kidneys, liver, pancreas, brain, central nervous system, a solid tumor, and a blood-borne tumor.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 94.0
- Lexical Diversity: 1.32432
- Patent Class: 544.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15325651', '15325692', '14154161', '14154173', '14154170']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8126947056885027
- 35 USC 102 Novelty (BERT): 0.5435479672846865
- Combined Prediction Score: 0.7857800318481211
- Mean Citation Score: 369.913976
- Max Citation Score: 422.80225
- Similarity Product: 233.6309832274765

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test